FDA Delays BLA for Lifileucel in Patients with Advanced Melanoma

The FDA has delayed a biologics license application (BLA) for lifileucel, a treatment for unresectable or metastatic melanoma, until the start of 2023 due to a request for additional data on the agent.
[Targeted Oncology]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News